202 related articles for article (PubMed ID: 29700772)
1. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.
Lalić N; Russel-Szymczyk M; Culic M; Tikkanen CK; Chubb B
Diabetes Ther; 2018 Jun; 9(3):1201-1216. PubMed ID: 29700772
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
Evans M; Chubb B; Gundgaard J
Diabetes Ther; 2017 Apr; 8(2):275-291. PubMed ID: 28210866
[TBL] [Abstract][Full Text] [Related]
4. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.
Pollock RF; Valentine WJ; Marso SP; Gundgaard J; Hallén N; Hansen LL; Tutkunkardas D; Buse JB;
Diabetes Ther; 2018 Jun; 9(3):1217-1232. PubMed ID: 29713962
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
[TBL] [Abstract][Full Text] [Related]
6. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
[TBL] [Abstract][Full Text] [Related]
7. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
[TBL] [Abstract][Full Text] [Related]
8. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
9. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.
Hunt B; Mocarski M; Valentine WJ; Langer J
Diabetes Ther; 2017 Jun; 8(3):531-544. PubMed ID: 28349444
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting.
Evans M; Mehta R; Gundgaard J; Chubb B
Diabetes Ther; 2018 Oct; 9(5):1919-1930. PubMed ID: 30097995
[TBL] [Abstract][Full Text] [Related]
11. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
12. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
J Med Econ; 2015 Jan; 18(1):56-68. PubMed ID: 25271378
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis.
Lau E; Salem A; Chan JCN; So WY; Kong A; Lamotte M; Luk A
Cost Eff Resour Alloc; 2019; 17():13. PubMed ID: 31303866
[TBL] [Abstract][Full Text] [Related]
17. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
Tarride JE; Husain M; Andersen A; Gundgaard J; Luckevich M; Mark T; Wagner L; Pieber TR
J Med Econ; 2021; 24(1):1318-1326. PubMed ID: 34763587
[TBL] [Abstract][Full Text] [Related]
18. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
20. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
